Paclitaxel /m2

Phase 2Small molecule

IInhibrx Biosciences, Inc

Paclitaxel /m2 is one of 88 small molecule programs targeting Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Small Cell Lung CancerActive, not recruiting

GrowthActive, not recruiting

Breast CancerPhase 2

Active, not recruiting

Small Cell Lung CancerPhase 2

Active, not recruiting

GrowthPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

DATROWAY

Daiichi Sankyo

Preclinical

4 2

MS Contin

Merck & Co.

Preclinical

2 3

Paclitaxel /m2

IInhibrx Biosciences, Inc

Phase 2

2 4

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 5

Spravato

WWim Janssens

Preclinical

2 6

Chirocaine

PPurdue Pharma LP

Preclinical

1 7

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 8

Nubain

AAultman Health Foundation

Preclinical

1 9

Fentanyl Citrate

IINSYS Therapeutics Inc

Preclinical

2 10

Vit D

PPost Graduate Institute of Medical Education and Research, Chandigarh

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1/2Active, not recruiting

Locally Advanced or Metastatic Solid Tumors

NCT04198766

Clinical

Trials by Indication[1]

Breast Cancer2 trials

Neurotoxicity Characterization Study of Nab-paclitaxel Versus Conventional Paclitaxel in Metastatic Breast Cancer

Completed·FFundacion Oncosur·Phase 2·NCT01763710·60 enrolled

Safety and Efficacy Study of Vintafolide and Vintafolide Plus Paclitaxel Compared to Paclitaxel Alone in Participants With Triple Negative Breast Cancer (TNBC) (MK-8109-004)

Withdrawn·EEndocyte·Phase 2·NCT01953536

Efficacy and Safety1 trial

Predictive Biomarker for Efficacy and Safety of Combination of Chemotherapy and Tislelizumab in NSCLC

Unknown status·HHao Long·Phase 2·NCT05244837·100 enrolled

Locally Advanced or Metastatic Solid Tumors1 trial

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Active, not recruiting·IInhibrx Biosciences, Inc·Phase 1/2·NCT04198766·296 enrolled

Growth1 trial

LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT01271725·74 enrolled

Small Cell Lung Cancer1 trial

Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients

Completed·SSpanish Lung Cancer Group·Phase 2·NCT03081689·46 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Paclitaxel /m2. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Paclitaxel /m2 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Paclitaxel /m2. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Inhibrx Biosciences, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IInhibrx Biosciences, Inc

Paclitaxel /m2

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Breast Cancer2 trials

Efficacy and Safety1 trial

Locally Advanced or Metastatic Solid Tumors1 trial

Growth1 trial

Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News